.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The CHANCE-2 randomized trial addressed a clinically important example of pharmacogenetics in stroke prevention. More than 6,000 Chinese patients with minor ischemic stroke or high-risk TIA who carried CYP2C19 loss-of-function alleles were assigned to ticagrelor or clopidogrel, both combined with aspirin for the short initial treatment period. Stroke occurred less often during 90-day follow-up with ticagrelor than with clopidogrel, while severe or moderate bleeding was similar between groups; overall bleeding was more frequent with ticagrelor. The study shows how genotype can influence the effectiveness of a commonly used secondary-prevention strategy. The population was almost entirely Han Chinese, so the magnitude of benefit may not transfer directly to every population. Nevertheless, the trial supports the broader principle of precision stroke medicine: when clopidogrel activation is impaired by genotype, an alternative P2Y12 strategy may reduce early recurrent stroke. For HCPs, pharmacogenetic testing is most useful when interpreted within local guidelines, patient bleeding risk and available testing pathways. The study directly complements IANCON's focus on stroke recurrence and newer approaches to secondary prevention.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The CHANCE-2 randomized trial addressed a clinically important example of pharmacogenetics in stroke prevention. More than 6,000 Chinese patients with minor ischemic stroke or high-risk TIA who carried CYP2C19 loss-of-function alleles were assigned to ticagrelor or clopidogrel, both combined with aspirin for the short initial treatment period. Stroke occurred less often during 90-day follow-up with ticagrelor than with clopidogrel, while severe or moderate bleeding was similar between groups; overall bleeding was more frequent with ticagrelor. The study shows how genotype can influence the effectiveness of a commonly used secondary-prevention strategy. The population was almost entirely Han Chinese, so the magnitude of benefit may not transfer directly to every population. Nevertheless, the trial supports the broader principle of precision stroke medicine: when clopidogrel activation is impaired by genotype, an alternative P2Y12 strategy may reduce early recurrent stroke. For HCPs, pharmacogenetic testing is most useful when interpreted within local guidelines, patient bleeding risk and available testing pathways. The study directly complements IANCON's focus on stroke recurrence and newer approaches to secondary prevention.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
